Skip to content
Results of ECAT EQA programme on DOACS
11th ECAT International Symposium
Speaker
Titel
Abstract
Presentation
M. van Essen
Results of ECAT EQA programme on DOACS
Related items
Analytical Information :
2
Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
Cases :
1
Acquired Hemophilia A, case study
ECAT Documents :
16
International external quality assessment for measurements of direct oral anticoagulants: results and recommendations.
Laboratory assesment of direct and indirect thrombin inhibitors
New developments in laboratory tests
Desired tests for monitoring new anticoagulation drugs
An update on new anticoagulation drugs
Measurement of new oral anticoagulans
ECAT survey results on direct oral anticoagulant testing
Monitoring new oral anticoagulants-Practical approach
The future of anticoagulation
Thrombosis webinar 2021, Antiphospholipid Antibody, Anticoagulation bridging
Medical device thrombosis
Interference of DOACS in coagulation tests
Guidance for laboratory testing of DOACS
Interferences in Lupus testing
Sinus thrombosis, past, present and future
Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories
Guidelines :
2
ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
Update Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, ICSH recommendations
Quality Issues :
1
External quality assessment for Rivaroxaban and Dabigatran
Questions or suggestions?
Clotpedia Support Form
Submit
Success
